Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins.
Normal urine inhibits both the growth and the aggregation of calcium oxalate monohydrate (COM) crystals but the molecules that inhibit aggregation are not well defined. We have developed a spectrophotometric assay method to measure the aggregation of COM crystals in vitro under conditions that avoid simultaneous crystal growth. At pH 7.2 and 90 mM NaCl, Tamm-Horsfall glycoprotein (THP) and nephrocalcin (NC), a major urinary inhibitor of COM crystal growth, inhibit COM crystal aggregation at concentrations as low as 2 X 10(-9) and 1 X 10(-8) M, respectively. When increasing NaCl to 270 mM or lowering pH to 5.7, inhibition by both glycoproteins, but more markedly by THP, is decreased. Urinary NC from calcium oxalate renal stone formers (SF NC) and NC isolated from calcium oxalate renal stones (stone NC) both inhibit COM crystal aggregation 10-fold less than NC from normal urine. Citrate is ineffective even at millimolar concentrations. Thus THP and NC are two major inhibitors of COM crystal aggregation in normal urine; SF NC and stone NC are defective aggregation inhibitors.
Hess
B
B
Nephrology Program, Pritzker School of Medicine, Chicago, Illinois.
Nakagawa
Y
Y
Coe
F L
FL
D000328:Adult; D002129:Calcium Oxalate / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D003460:Crystallization; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009088:Mucoproteins / Q000494:pharmacology*; D009994:Osmolar Concentration; D058949:Uromodulin; D014783:Viscosity
D006023:Glycoproteins; D009088:Mucoproteins; C548612:UMOD protein, human; D058949:Uromodulin; C029490:nephrocalcin; D002129:Calcium Oxalate